|
Dear Oregon Providers,
Thank you for your role in supporting access to COVID-19 therapeutics in Oregon. The Oregon Health Authority (OHA) appreciates your partnership as we continue navigating the federal allocation process.
Incidence of SARS-CoV-2 Omicron BA.2 variant is increasing in Oregon. The monoclonal antibody Sotrovimab appears to have limited effectiveness against this variant. The federal government will suspend allocation of Sotrovimab to Oregon next week. If your qualifying site has requested Sotrovimab, OHA has fulfilled your order but will no longer be allocating Sotrovimab after this week.
Please visit this webpage for more information: https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Sotrovimab/Pages/default.aspx
In the meantime, clinicians might wish to consider other treatments for patients with laboratory-confirmed COVID-19 who are at high risk for severe illness. Options, in order of preference based on guidance from the National Institutes of Health, include Paxlovid (available through allocation from Oregon Health Authority), Remdesivir (available commercially), and either Molnupiravir or Bebtelovimab (both available through allocation from OHA).
Additionally, the federal government has released the Test to Treat Locator to make it easier to find Test to Treat (T2T) locations. This locator allows you to:
- Enter the appropriate address, city or zip code
- Select the desired distance from the location entered (in miles)
- Search locations with testing, medical assessment by a provider, and dispense COVID-19 antivirals (T2T)
-
Search locations to fill a prescription (Federal Retail Pharmacy Therapeutic Program sites included)
The federal T2T model quickly connects eligible individuals who are at high risk of severe COVID-19 to appropriate treatments and aims to increase access to lifesaving COVID-19 treatments that must be given quickly to be effective. These locations will provide access for people to get tested, receive a prescription from a health care provider, and fill that prescription, all at one location. OHA is working on adding additional sites that fit federal criteria to be a T2T site.
OHA is allocating a portion of oral COVID-19 treatment Molnupiravir to two FRPTP sites, Rite Aid and Walgreens. These sites were selected based on OHA's assessment of strategic geographical distribution. The federally registered pharmacies have received their allocations and have distributed them across their stores. Please call to verify supply before sending a prescription to Rite Aid or Walgreens. OHA is working on broadening access to therapeutics to rural communities by exploring additional pharmacies.
Please utilize the tool to help connect patients to a T2T site or send a prescription to a FRPTP site.
Thank you,
OHA COVID-19 Therapeutics Team
OHA.Therapeutics@dhsoha.state.or.us
|
